Company Filing History:
2 out of 2 
2 out of 205 
1 out of 1,744 
Years Active: 2022-2025
Title: **Innovative Insights into Mathilde Metna: A Pioneer in Cannabinoids-Related Disorders**
Introduction
Mathilde Metna, an accomplished inventor based in Bordeaux, France, has made significant strides in the field of cannabinoid-related disorders. With a focus on innovative treatments, she holds a patent that reflects her commitment to advancing medical science.
Latest Patents
Mathilde Metna is credited with one patent: 3β-(4-methoxybenzyloxy)pregn-5-en-20-one. This invention is a specific pregnenolone derivative intended for use in the treatment of cannabinoids-related disorders. The compound, identified as Formula (I), represents a promising advancement in the therapeutic management of conditions associated with cannabinoids.
Career Highlights
Throughout her career, Mathilde has been associated with prominent organizations such as Aelis Farma and Inserm (Institut National de la Santé et de la Recherche Médicale). Her work within these institutions has allowed her to explore innovative solutions that address crucial health challenges.
Collaborations
Mathilde Metna has collaborated with esteemed colleagues, including Pier Vincenzo Piazza and Sandy Fabre. These partnerships have facilitated a collaborative approach to research, enhancing the potential impact of their collective findings in the field.
Conclusion
In summary, Mathilde Metna stands out as a pioneering inventor in cannabinoid-related medical treatments. Her patent underscores her dedication to developing effective therapies and reflects her significant contributions to medical research. As the landscape of innovation continues to evolve, inventors like Mathilde play a crucial role in shaping the future of healthcare.